Cyclo (glycyl-L-leucyl)

Cyclo (glycyl-L-leucyl) (Cyclo (leu-gly) ), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo (glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo (glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304) -induced dyskinesias[1][2].

Product Specifications

CAS Number

[5845-67-0]

Product Name Alternative

Cyclo (leu-gly)

UNSPSC

12352209

Hazard Statement

H302, H317

Target

Dopamine Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cyclo-glycyl-l-leucyl.html

Purity

99.79

Solubility

H2O

Smiles

CC(C[C@H]1C(NCC(N1)=O)=O)C

Molecular Formula

C8H14N2O2

Molecular Weight

170.21

Precautions

H302, H317

References & Citations

[1]J Z Fields, et al. The effects of cyclo (leucyl-glycyl) on nigrostriatal dopaminergic supersensitivity--inhibition of apomorphine-induced climbing. Neuropeptides. 1990 Aug;16 (4) :207-11.|[2]H N Bhargava, et al. Cyclo (leucylglycine) inhibits the development of morphine induced analgesic tolerance and dopamine receptor supersensitivity in rats. Life Sci. 1980 Jul 14;27 (2) :117-23.